Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

Haematologica. 2012 Sep;97(9):e34-5. doi: 10.3324/haematol.2012.067629.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Chromosome Aberrations*
  • Chromosomes, Human, Pair 5 / genetics*
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Myelodysplastic Syndromes / drug therapy*
  • Thalidomide / analogs & derivatives*

Substances

  • Antineoplastic Agents
  • Thalidomide